JP6607854B2 - Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット - Google Patents

Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット Download PDF

Info

Publication number
JP6607854B2
JP6607854B2 JP2016529843A JP2016529843A JP6607854B2 JP 6607854 B2 JP6607854 B2 JP 6607854B2 JP 2016529843 A JP2016529843 A JP 2016529843A JP 2016529843 A JP2016529843 A JP 2016529843A JP 6607854 B2 JP6607854 B2 JP 6607854B2
Authority
JP
Japan
Prior art keywords
carrier molecule
tilmanocept
composition
carrier
receptor substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016529843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527252A (ja
JP2016527252A5 (enExample
Inventor
コープ，フレデリック
ブルー，マイケル
メッツ，ウェンディ
シュレジンガー，ラリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navidea Biopharmaceuticals Inc
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of JP2016527252A publication Critical patent/JP2016527252A/ja
Publication of JP2016527252A5 publication Critical patent/JP2016527252A5/ja
Application granted granted Critical
Publication of JP6607854B2 publication Critical patent/JP6607854B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
JP2016529843A 2013-07-22 2014-07-22 Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット Active JP6607854B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361857232P 2013-07-22 2013-07-22
US61/857,232 2013-07-22
US201361879649P 2013-09-18 2013-09-18
US61/879,649 2013-09-18
PCT/US2014/047708 WO2015013341A1 (en) 2013-07-22 2014-07-22 Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders

Publications (3)

Publication Number Publication Date
JP2016527252A JP2016527252A (ja) 2016-09-08
JP2016527252A5 JP2016527252A5 (enExample) 2017-08-31
JP6607854B2 true JP6607854B2 (ja) 2019-11-20

Family

ID=51352773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016529843A Active JP6607854B2 (ja) 2013-07-22 2014-07-22 Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット

Country Status (11)

Country Link
US (2) US20150023876A1 (enExample)
EP (1) EP3024493A1 (enExample)
JP (1) JP6607854B2 (enExample)
KR (2) KR20210095972A (enExample)
CN (2) CN105764529A (enExample)
AU (3) AU2014293198A1 (enExample)
CA (1) CA2918782C (enExample)
HK (1) HK1225623A1 (enExample)
IL (1) IL243645B (enExample)
WO (1) WO2015013341A1 (enExample)
ZA (1) ZA201600453B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
JP6722663B2 (ja) * 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
JP2018528235A (ja) * 2015-09-25 2018-09-27 セリーン・エルエルシー Ｓｎ−１１７ｍ標識マンノース結合デキストランアミン
MX2019003897A (es) * 2016-10-04 2019-11-18 Cardinal Health 414 Llc Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos.
MX2019004033A (es) * 2016-10-07 2019-12-05 Navidea Biopharmaceuticals Inc Compuestos y composiciones para el tratamiento de la leishmaniasis y metodos de diagnostico y tratamiento que utilizan los mismos.
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
US11363709B2 (en) 2017-02-24 2022-06-14 BWXT Isotope Technology Group, Inc. Irradiation targets for the production of radioisotopes
US11286172B2 (en) 2017-02-24 2022-03-29 BWXT Isotope Technology Group, Inc. Metal-molybdate and method for making the same
JP2020521021A (ja) * 2017-05-19 2020-07-16 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド Ｃｄ２０６＋マクロファージ特異的分子画像化のプローブ組成物および方法、ならびにヒトにおける動脈壁マクロファージ浸潤の非侵襲的定量化
EP3655107A4 (en) * 2017-07-21 2021-04-28 Navidea Biopharmaceuticals, Inc. Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions
CN114025666A (zh) * 2019-01-25 2022-02-08 纳维迪亚生物制药有限公司 用于评估巨噬细胞介导的病理学的组合物和方法
GB201902810D0 (en) * 2019-03-01 2019-04-17 Vidya Holdings Ltd Disposition of reagents in assay device
MX2021011703A (es) * 2019-03-27 2022-01-06 Navidea Biopharmaceuticals Inc Composiciones y métodos para alterar el fenotipo de macrófagos.
WO2021034953A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
CN115151264B (zh) * 2019-09-30 2024-03-12 纳维迪亚生物制药有限公司 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法
GB201915222D0 (en) * 2019-10-21 2019-12-04 Univ Court Univ Of Glasgow Diagnostic and prognostic biomarkers of disease remission in rheumatoid arthritis
JP2023533405A (ja) * 2020-07-08 2023-08-03 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成
WO2022157373A1 (en) * 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
CN113899909A (zh) * 2021-09-30 2022-01-07 上海交通大学医学院附属瑞金医院 可溶性cd206在制备抗中性粒细胞胞浆抗体相关性血管炎诊断试剂盒中的应用
EP4472643A1 (en) 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
WO2023183922A2 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive self-blocking with unlabeled manocept imaging agents
EP4525882A1 (en) 2022-05-20 2025-03-26 Navidea Biopharmaceuticals, Inc. Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
US12404349B2 (en) 2022-10-03 2025-09-02 Navidea Biopharmaceuticals, Inc. Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers
WO2024178142A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
CN119592679B (zh) * 2024-11-25 2025-06-24 中日友好医院(中日友好临床医学研究所) 一种用于评估皮肌炎/抗合成酶综合征相关间质性肺疾病严重程度及预后的新型标记物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE277642T1 (de) * 1999-05-14 2004-10-15 Univ California Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe
JP2004085929A (ja) * 2002-08-27 2004-03-18 Fuji Photo Optical Co Ltd 光学素子
US20090311182A1 (en) * 2004-03-31 2009-12-17 Dong Wang Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
SG166016A1 (en) * 2009-04-16 2010-11-29 Fan Wang Yiang Financial education planner and method of using thereof
US9101674B2 (en) * 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US20130330274A1 (en) * 2012-05-22 2013-12-12 University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for detecting and treating cancer

Also Published As

Publication number Publication date
AU2020200293A1 (en) 2020-02-06
CN105764529A (zh) 2016-07-13
AU2022205225A1 (en) 2022-08-04
IL243645B (en) 2019-12-31
WO2015013341A1 (en) 2015-01-29
KR20160055791A (ko) 2016-05-18
US20220016272A1 (en) 2022-01-20
AU2020200293B2 (en) 2022-04-21
KR102284389B1 (ko) 2021-08-03
EP3024493A1 (en) 2016-06-01
CA2918782A1 (en) 2015-01-29
ZA201600453B (en) 2019-09-25
IL243645A0 (en) 2016-02-29
JP2016527252A (ja) 2016-09-08
CN114377143A (zh) 2022-04-22
AU2014293198A1 (en) 2016-02-04
HK1225623A1 (zh) 2017-09-15
US20150023876A1 (en) 2015-01-22
KR20210095972A (ko) 2021-08-03
CA2918782C (en) 2024-03-12

Similar Documents

Publication Publication Date Title
JP6607854B2 (ja) Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット
EP3156078B1 (en) Fucoidans as ligands for the diagnosis of degenerative pathologies
Kryza et al. Biodistribution study of nanometric hybrid gadolinium oxide particles as a multimodal SPECT/MR/optical imaging and theragnostic agent
US11154625B2 (en) Fucoidans as ligands for the diagnosis of degenerative pathologies
KR20070106711A (ko) 이중 영상화 및 방사선화학요법용 접합체: 조성물,제조방법 및 적용
US20220031873A1 (en) Multi-Modal Contrast Agent For Medical Imaging
US20210338848A1 (en) Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
JP6310567B2 (ja) アテローム動脈硬化映像化用組成物、及びそれを用いたアテローム動脈硬化の診断方法
HK40073647A (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
US20220280659A1 (en) Targeted Nanoparticles of Well-Defined and Reproducible Sizes
JP6395880B2 (ja) 変性病変の診断のためのリガンドとしてのフコイダン
JP6099055B2 (ja) 変性病変の診断のためのリガンドとしてのフコイダン
JP2011506273A (ja) 新規イメージング法
Rai ENGINEERING FUNCTIONALIZED DIAMOND NANOPARTICLES FOR GENE DELIVERY: BIODISTRIBUTION STUDIES
CN116370660A (zh) Pecam-1靶向性诊疗一体化纳米探针及其制备方法和应用
Müller et al. Folate Receptor-Targeted Radionuclide Imaging Agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180815

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180823

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191021

R150 Certificate of patent or registration of utility model

Ref document number: 6607854

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250